However, since we found that imatinib treatment downregulates CD49f in Ph‐positive ALL cell lines, application of CD49f to the flow cytometric MRD evaluation in Ph‐positive ALL patients treated with imatinib‐combined chemotherapy must be considered cautiously. The gene discussed is ITGA6; the disease is acute lymphoblastic leukemia.